双重阻断 CD47 和 HER2 可消除放射抵抗性乳腺癌细胞。

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells.

机构信息

Department of Radiation Oncology, University of California Davis, Sacramento, CA, USA.

Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.

出版信息

Nat Commun. 2020 Sep 14;11(1):4591. doi: 10.1038/s41467-020-18245-7.

Abstract

Although the efficacy of cancer radiotherapy (RT) can be enhanced by targeted immunotherapy, the immunosuppressive factors induced by radiation on tumor cells remain to be identified. Here, we report that CD47-mediated anti-phagocytosis is concurrently upregulated with HER2 in radioresistant breast cancer (BC) cells and RT-treated mouse syngeneic BC. Co-expression of both receptors is more frequently detected in recurrent BC patients with poor prognosis. CD47 is upregulated preferentially in HER2-expressing cells, and blocking CD47 or HER2 reduces both receptors with diminished clonogenicity and augmented phagocytosis. CRISPR-mediated CD47 and HER2 dual knockouts not only inhibit clonogenicity but also enhance macrophage-mediated attack. Dual antibody of both receptors synergizes with RT in control of syngeneic mouse breast tumor. These results provide the evidence that aggressive behavior of radioresistant BC is caused by CD47-mediated anti-phagocytosis conjugated with HER2-prompted proliferation. Dual blockade of CD47 and HER2 is suggested to eliminate resistant cancer cells in BC radiotherapy.

摘要

尽管癌症放射治疗 (RT) 的疗效可以通过靶向免疫疗法来增强,但肿瘤细胞辐射诱导的免疫抑制因素仍有待确定。在这里,我们报告 CD47 介导的抗吞噬作用与放射性耐药乳腺癌 (BC) 细胞和 RT 治疗的小鼠同基因 BC 中的 HER2 同时上调。在预后不良的复发性 BC 患者中更频繁地检测到这两种受体的共表达。CD47 在 HER2 表达细胞中优先上调,阻断 CD47 或 HER2 可减少这两种受体的克隆形成能力并增强吞噬作用。CRISPR 介导的 CD47 和 HER2 双重敲除不仅抑制克隆形成能力,而且增强巨噬细胞介导的攻击。两种受体的双抗体协同作用与 RT 控制同基因小鼠乳腺肿瘤。这些结果提供了证据,表明放射性耐药 BC 的侵袭性行为是由 CD47 介导的抗吞噬作用与 HER2 引起的增殖相结合引起的。建议双重阻断 CD47 和 HER2 以消除 BC 放疗中的耐药癌细胞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee2a/7490264/0cc2b53c441e/41467_2020_18245_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索